Significance of immunohistochemical c-ErbB-2 product localisation pattern for prognosis in human breast cancer

Pathology and Oncology Research

Volumn 7, Issue 3, 2001, Pages 190-196

  Aziz, Syed Abdus ^a   Pervez, Shahid ^a,c   Khan, Shaista ^b   Kayani, Naila ^c   Azam, Syed Igbal ^c   Rahbar, Mohammed Hussain ^a  

^a Pathology Department   (Pakistan)

^b Department of Surgery ^*  (Pakistan)

^c AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST TUMOR; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE;

EID: 0035236805     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03032348     Document Type: Article

References (5)

1. Guido S, Georg F, Joachim T: Fluorescence in Situ Hybridization for detecting C-ErbB-2 amplification in breast tumor fine needle aspiration biopsies. Acta Cytologica 40:164-173, 1996.
2. Muss HE, Thor AD, Berry DA: Cerb-B-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994.
3. William C: More than one way to look for HER-2. Cap Today 13:31-54, 1999.
4. Perren TJ: C-ErbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 63:328-332, 1991.
5. van de Vijver MJ, Peterse JL, Mooi WJ: Neu-protein over expression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239-1245, 1988.